The Negative Prognostic Value of TRAIL Overexpression in Oral Squamous Cell Carcinomas Does Not Preclude the Potential Therapeutic Use of Recombinant TRAIL

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2010 Nov 19

PMID 21086019

Citations 1

Authors

Francesco Carinci

Lorenzo Monasta

Corrado Rubini

Daniela Stramazzotti

Annalisa Palmieri

Elisabetta Melloni

Alex Knowles

Luca Ronfani

Giorgio Zauli

Paola Secchiero

Affiliations

Soon will be listed here.

Citing Articles

The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

Bisheshar S, de Ruiter E, Devriese L, Willems S Oncoimmunology. 2020; 9(1):1747345.

PMID: 32363116 PMC: 7185215. DOI: 10.1080/2162402X.2020.1747345.

References

Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y . A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol. 1999; 163(9):4886-93. View

Koyama S, Koike N, Adachi S . Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol. 2002; 128(2):73-9. DOI: 10.1007/s004320100292. View

Re M, Zauli G, Gibellini D, Furlini G, Ramazzotti E, Monari P . Uninfected haematopoietic progenitor (CD34+) cells purified from the bone marrow of AIDS patients are committed to apoptotic cell death in culture. AIDS. 1993; 7(8):1049-55. DOI: 10.1097/00002030-199308000-00004. View

Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L . Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004; 104(8):2418-24. DOI: 10.1182/blood-2004-04-1294. View

Al-Swiahb J, Chen C, Chuang H, Fang F, Tasi H, Chien C . Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol. 2010; 6(5):837-50. DOI: 10.2217/fon.10.35. View

Morris L, Patel S, Shah J, Ganly I . Squamous cell carcinoma of the oral tongue in the pediatric age group: a matched-pair analysis of survival. Arch Otolaryngol Head Neck Surg. 2010; 136(7):697-701. PMC: 3005582. DOI: 10.1001/archoto.2010.94. View

Ord R, Blanchaert Jr R . Current management of oral cancer. A multidisciplinary approach. J Am Dent Assoc. 2002; 132 Suppl:19S-23S. DOI: 10.14219/jada.archive.2001.0384. View

Kreppel M, Eich H, Kubler A, Zoller J, Scheer M . Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol. 2010; 102(5):443-9. DOI: 10.1002/jso.21547. View

Secchiero P, Zauli G . Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol. 2007; 15(1):42-8. DOI: 10.1097/MOH.0b013e3282f15fa6. View

10.

Song K, Goke R, Wilmen A, Seidel C, Goke A, Hilliard B . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med. 2000; 191(7):1095-104. PMC: 2193179. DOI: 10.1084/jem.191.7.1095. View

11.

Macher-Goeppinger S, Aulmann S, Tagscherer K, Wagener N, Haferkamp A, Penzel R . Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res. 2009; 15(2):650-9. DOI: 10.1158/1078-0432.CCR-08-0284. View

12.

van Geelen C, Westra J, de Vries E, Boersma-van Ek W, Zwart N, Hollema H . Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol. 2006; 24(31):4998-5004. DOI: 10.1200/JCO.2006.06.8809. View

13.

Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S . Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol. 1998; 160(8):3891-8. View

14.

Ishimura N, Isomoto H, Bronk S, Gores G . Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2005; 290(1):G129-36. DOI: 10.1152/ajpgi.00242.2005. View

15.

Itashiki Y, Harada K, Ferdous T, Yoshida H . Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2007; 27(4B):2365-75. View

16.

Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C . TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol. 2007; 214(1):117-25. DOI: 10.1002/jcp.21165. View

17.

Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P . Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem. 2003; 86(1):126-35. DOI: 10.1046/j.1471-4159.2003.01805.x. View

18.

Di Pietro R, Zauli G . Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol. 2004; 201(3):331-40. DOI: 10.1002/jcp.20099. View

19.

Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E . Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation. 2006; 114(14):1522-30. DOI: 10.1161/CIRCULATIONAHA.106.643841. View

20.

Soria J, Smit E, Khayat D, Besse B, Yang X, Hsu C . Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010; 28(9):1527-33. DOI: 10.1200/JCO.2009.25.4847. View